Why Shares of Moderna Are Up Today
Shares of Moderna (NASDAQ: MRNA) are up more than 4% as of 3:30 p.m. EDT, as the one-two punch of new data and corporate mandates makes the case for continued demand.
Image source: Getty Images.
A study by Belgian researchers reported in the Journal of the American Medical Association highlighted the superiority of Moderna's COVID-19 vaccine compared to its biggest rival. Of the more than 1,600 participants in the study, those who received Moderna's jab had almost twice the level of antibodies as those who received Comirnaty -- the vaccine from Pfizer and BioNTech. The researchers did not conclude that the shot offered more protection, as antibodies are only one part of the body's immune defense. Still, it's yet another potential reason to choose the company's drug over others.
Source Fool.com
